The levels of IL-6, IL-1β and TNF-α were significantly increased in the liver tissues of rats in the model group compared with those in the control group (p < 0.01), and JGXZ treatment significantly reduced the levels of IL-6, IL-1β, and TNF-α in the liver tissues of NAFLD rats compared with that in the model group (p < 0.01 and p < 0.05, Figure 3(c)). Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.